REPLIMUNE GROUP INC. news, videos and press releases
For more news please use our advanced search feature.
REPLIMUNE GROUP INC. - More news...
REPLIMUNE GROUP INC. - More news...
- Replimune to Present at the 2025 Jefferies Global Healthcare Conference
- Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
- Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced Melanoma
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune Announces RP2 Development Program Advances with First Patients Enrolled in Metastatic Uveal Melanoma and Hepatocellular Carcinoma Clinical Trials
- Replimune to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Replimune Announces Pricing of Upsized Public Offering
- Replimune Announces Proposed Public Offering
- Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway
- Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
- Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune to Present at Two Upcoming Investor Conferences
- Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
- Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024
- Stockholders Vote to Elect Madhavan Balachandran to Board of Directors
- Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
- Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
- Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
- Replimune to Present at Two Upcoming Investor Conferences
- Replimune Announces $100 Million Private Placement Financing
- Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
